Full-Time

Medical Science Liaison

Blueprint Medicines

Blueprint Medicines

501-1,000 employees

Biopharma developing kinase inhibitors for cancer

No salary listed

Schwalmstadt, Germany + 5 more

More locations: Ansbach, Germany | Taucha, Germany | Dresden, Germany | Frankfurt, Germany | Sankt Wendel, Germany

In Person

Residence in Germany preferred; willing to travel within Germany; field-based role.

Category
Biology & Biotech (1)

Get referred to Blueprint Medicines

See people who can refer or advise you

Requirements
  • Advanced Clinical/Science degree or professional credentials required (PhD, MD/DO, PharmD, MSc)
  • 3+ years of experience in the biotech or pharmaceutical industry in Medical Affairs
Responsibilities
  • Identify key opinion leaders and cultivate a network of experts for disease areas of focus
  • Respond to unsolicited requests and engage in meaningful, peer-to-peer scientific exchange of complex medical and scientific information with the oncology, hematology, pathology, and rare disease community
  • Provide internal stakeholders with feedback and insights from interactions and discussions with HCPs.
  • Accurately profile country and define local dynamics related to patient diagnosis and referral for treatment
  • Deliver medical/scientific presentations to internal & external stakeholders
  • Assist with company-sponsored clinical trials and facilitation of investigator-initiated trials (ISTs)
  • Lead planning and execution of regional advisory boards
  • Collaborate with cross functional partners on internal projects and external initiatives
  • Provide educational meeting support at scientific congresses
  • Support training of cross functional teams
  • Adhere to corporate and healthcare compliance guidance in all activities, including those related to clinical trials, scientific interactions with internal and external groups, and responses to unsolicited requests for medical/scientific information
  • Foster and maintain Blueprint’s positive and innovative culture
  • Significant travel is required as part of this position
Desired Qualifications
  • 3+ years of experience in the biotech or pharmaceutical industry in Medical Affairs, with experience working with cross-functional in-house and field-based teams
  • Rare Disease and/or oncology/hematology experience strongly preferred; combined is ideal
  • Immunology/allergy or dermatology experience of advantage
  • Strong interpersonal, presentation and communication skills and demonstrated ability to work collaboratively in a dynamic, team-oriented environment
  • Fluent written and spoken communication skills in English and in local language of geographic location where the position is based
  • Creative problem-solving skills
  • Positive, solutions-oriented mindset
  • Demonstrated self-starter and team player with strong interpersonal skills
  • Adept, nimble, energetic, and comfortable in a fast-paced, dynamic, and collaborative environment
  • Capable of taking a hands-on approach and willing to “roll up one’s sleeves.”
  • Ensure compliance with corporate rules and local regulations
  • Strong analytical skills, especially with regard to understanding and interpreting scientific and clinical research and literature, are essential
  • Commitment to our Core Values: Patients First, Thoughtfulness, Urgency, Trust, Optimism

Blueprint Medicines develops and commercializes kinase inhibitors for cancer and other diseases. Its lead product, Ayvakit (avapritinib), blocks enzymes that drive tumor growth in gastrointestinal stromal tumors with PDGFRA exon 18 mutations. The company also has a pipeline of other kinase inhibitors in clinical development for lung, breast, and blood cancers, plus preclinical programs in immunology and rare diseases. By performing discovery, development, and commercialization in-house, it aims to bring targeted therapies to patients with unmet medical needs and expand its global oncology portfolio.

Company Size

501-1,000

Company Stage

IPO

Headquarters

Cambridge, Massachusetts

Founded

2011

Get referred to Blueprint Medicines

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Sanofi reported €367 million Ayvakit net sales in first-half 2026, validating demand.
  • Blueprint's HARBOR elenestinib study and BLU-808 trials keep generating optionality in 2026.
  • Sanofi's $9.1 billion acquisition funds global commercialization and near-term pipeline development.

What critics are saying

  • Sanofi is cutting 229 Blueprint jobs in Cambridge from October 2026 through June 2027.
  • Two legacy Cambridge offices close, and remaining Blueprint staff relocate to Sanofi's campus.
  • Ayvakit concentration is dangerous; a Sanofi integration miss can erase Blueprint's standalone identity.

What makes Blueprint Medicines unique

  • Ayvakit remains the first approved systemic mastocytosis therapy, protected by rare-disease specialization.
  • Blueprint built deep KIT biology expertise across avapritinib, elenestinib, and BLU-808 programs.
  • Its Cambridge mast-cell franchise uniquely spans oncology and immunology, not generic kinase discovery.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Retirement Plan

401(k) Company Match

Unlimited Paid Time Off

Commuter Benefits

Mental Health Support

Employee Stock Purchase Plan

Parental Leave

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

1%

2 year growth

1%
pharmaphorum
Aug 17th, 2026
Sanofi to lay off 229 Blueprint employees, close offices.

Sanofi to lay off 229 Blueprint employees, close offices. Sanofi is laying off 229 former Blueprint Medicines employees in Cambridge, MA and closing two legacy Blueprint facilities. The news comes just over a year after Sanofi's $9 billion acquisition of Blueprint, one of the biggest deals of 2025. Boston Business Journal broke the news, which pharmaphorum has independently verified with the company. "As part of the integration following our acquisition of Blueprint Medicines in July 2025, we made thoughtful organisational decisions to align our structure with our long-term business priorities and the needs of our commercial portfolio and pipeline," Sanofi said in an emailed statement. "These decisions were made carefully to position the organisation for future success while continuing to deliver for patients. Many Blueprint employees are joining Sanofi. Those affected by these decisions have already been informed and we will continue to provide multiple avenues of support through their transitions." Blueprint's facilities at 45 Sidney St and 38 Sidney St in Cambridge are closing, with remaining Blueprint employees reporting to Sanofi's East Cambridge office. Since the acquisition was finalised in July 2025, there's already been an exodus of Blueprint talent at the top levels of the company. All 13 members of Blueprint's leadership team (as listed on their website at the time) have left the company in the last year, with most departing in October of last year, according to LinkedIn. Chief scientific officer Percy Carter has been leading preclinical and translational sciences at Pfizer, chief commercial officer Philina Lee is now CEO at AdvanceCell, R&D president Fouad Namouni is CEO at Synolo Therapeutics, and three separate members of the team - chief medical officer Dr Becker Hewes, chief business officer Sherwin Sattarzadeh, and SVP corporate affairs Jim Baker - have landed in similar roles at Damora Therapeutics, a Boston biotech focused on blood disorders. Sanofi acquired Blueprint to secure the rights to Ayvakit/Ayvakyt (avapritinib), a tyrosine kinase inhibitor (TKI) that targets the KIT D816V mutation in ASM, an umbrella term that covers multiple disorders, including aggressive systemic mastocytosis, systemic mastocytosis with an associated haematological neoplasm (SM-AHN), and mast cell leukaemia (MCL). Ayvakit is the only approved medicine for ASM, which causes symptoms like itching, fever, abdominal pain, and nausea, and can also lead to organ damage, bone fractures, and anaemia. People with ASM typically have a life expectancy ranging from six months to around three-and-a-half years. According to recent Sanofi financial reports, Aykavit earned the company €367 million in net sales in the first half of 2026. 17 August, 2026

Fusacq
Jun 2nd, 2025
Sanofi Acquires Blueprint Medicines Biotech

Sanofi has acquired the American biotech company Blueprint Medicines, which specializes in systemic mastocytosis, a rare disease characterized by abnormal activation or proliferation of mast cells in tissues, most commonly the skin and bone marrow.

Google
Jun 2nd, 2025
Sanofi Acquires Blueprint for $9.1B

Sanofi is set to acquire Blueprint Medicines for an equity value of $9.1 billion, according to Bloomberg.

Investors Hangout
Jun 2nd, 2025
Sanofi Acquires Blueprint for $9.1B

Sanofi is acquiring Blueprint Medicines for approximately $9.1 billion, enhancing its immunology portfolio. This acquisition includes Ayvakit, the only FDA-approved treatment for systemic mastocytosis, and promising therapies like elenestinib and BLU-808. Sanofi will finance the deal with cash and new debt, expecting it to boost gross margin and operating income post-2026. The merger aligns with Sanofi's strategy to lead in immunology and address rare diseases.

The Gazette
Jun 2nd, 2025
Sanofi to buy US biopharma group Blueprint for up to $9.5 billion

PARIS (Reuters) -France's Sanofi has agreed to buy U.S.-based Blueprint Medicines Corporation for up to $9.5 billion to boost its position in rare immunology diseases, in the biggest deal struck by a European healthcare company so far this year, according to LSEG data.